160 related articles for article (PubMed ID: 20688946)
1. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Okamoto I; Kaneda H; Satoh T; Okamoto W; Miyazaki M; Morinaga R; Ueda S; Terashima M; Tsuya A; Sarashina A; Konishi K; Arao T; Nishio K; Kaiser R; Nakagawa K
Mol Cancer Ther; 2010 Oct; 9(10):2825-33. PubMed ID: 20688946
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
Mross K; Stefanic M; Gmehling D; Frost A; Baas F; Unger C; Strecker R; Henning J; Gaschler-Markefski B; Stopfer P; de Rossi L; Kaiser R
Clin Cancer Res; 2010 Jan; 16(1):311-9. PubMed ID: 20028771
[TBL] [Abstract][Full Text] [Related]
3. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
Reck M; Kaiser R; Eschbach C; Stefanic M; Love J; Gatzemeier U; Stopfer P; von Pawel J
Ann Oncol; 2011 Jun; 22(6):1374-1381. PubMed ID: 21212157
[TBL] [Abstract][Full Text] [Related]
4. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois A; Huober J; Stopfer P; Pfisterer J; Wimberger P; Loibl S; Reichardt VL; Harter P
Ann Oncol; 2010 Feb; 21(2):370-375. PubMed ID: 19889612
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Bousquet G; Alexandre J; Le Tourneau C; Goldwasser F; Faivre S; de Mont-Serrat H; Kaiser R; Misset JL; Raymond E
Br J Cancer; 2011 Nov; 105(11):1640-5. PubMed ID: 22027711
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Ledermann JA; Hackshaw A; Kaye S; Jayson G; Gabra H; McNeish I; Earl H; Perren T; Gore M; Persic M; Adams M; James L; Temple G; Merger M; Rustin G
J Clin Oncol; 2011 Oct; 29(28):3798-804. PubMed ID: 21859991
[TBL] [Abstract][Full Text] [Related]
8. An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
Kropff M; Kienast J; Bisping G; Berdel WE; Gaschler-Markefski B; Stopfer P; Stefanic M; Munzert G
Anticancer Res; 2009 Oct; 29(10):4233-8. PubMed ID: 19846979
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
10. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
11. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
Ellis PM; Kaiser R; Zhao Y; Stopfer P; Gyorffy S; Hanna N
Clin Cancer Res; 2010 May; 16(10):2881-9. PubMed ID: 20460487
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Ueda Y; Shimoyama T; Murakami H; Yamamoto N; Yamada Y; Arioka H; Tamura T
Cancer Chemother Pharmacol; 2011 May; 67(5):1101-9. PubMed ID: 20676675
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Kudo K; Arao T; Tanaka K; Nagai T; Furuta K; Sakai K; Kaneda H; Matsumoto K; Tamura D; Aomatsu K; De Velasco MA; Fujita Y; Saijo N; Kudo M; Nishio K
Clin Cancer Res; 2011 Mar; 17(6):1373-81. PubMed ID: 21131553
[TBL] [Abstract][Full Text] [Related]
14. Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
Murakami H; Ueda Y; Shimoyama T; Yamamoto N; Yamada Y; Arioka H; Tamura T
Cancer Chemother Pharmacol; 2011 May; 67(5):1119-28. PubMed ID: 20676674
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
Stopfer P; Rathgen K; Bischoff D; Lüdtke S; Marzin K; Kaiser R; Wagner K; Ebner T
Xenobiotica; 2011 Apr; 41(4):297-311. PubMed ID: 21204634
[TBL] [Abstract][Full Text] [Related]
16. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
[TBL] [Abstract][Full Text] [Related]
18. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Shimizu T; Fujiwara Y; Yamada K; Tamura T; Watanabe H; Sun YN; Bass MB; Seki M
Cancer Chemother Pharmacol; 2010 Oct; 66(5):935-43. PubMed ID: 20107802
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
